The 5 analysts offering 12-month price forecasts for Outlook Therapeutics Inc have a median target of 6.00, with a high estimate of 9.00 and a low estimate of 3.25. The median estimate represents a +365.12% increase from the last price of 1.29.
The current consensus among 5 polled investment analysts is to Buy stock in Outlook Therapeutics Inc. This rating has held steady since May, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.12
Reporting Date Aug 12
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.